Chronic low back pain
Conditions
Brief summary
• Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1
Detailed description
Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at the follow-up visit [Time Frame:, Day 21], Change from baseline in Neuropathic Pain Symptom Inventory (NPSI) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at the follow-up visit [ Time Frame: Day 21], Number of Participants Withdrawn Due to Lack of Efficacy Week 1, Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 1, Change from Baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 1, Patient Global Impression of Change (PGI-C) Score Week 1, Change From Baseline in European Quality of Life Questionnaire-5 Dimension-5 Level (EQ-5D-5L) to Week 1, Change From Baseline in Work Productivity and Activity Impairment (WPAI) Instrument at Week 1, Number of rescue interventions up to Week 1, Physical examination (see 7.1.2) [time frame: end of treatment visit (Week 1) or withdrawal]., Vital signs: blood pressure, heart rate and Body Temperature and ECG [time frame: end of treatment visit (Week 1) or early withdrawal]., Safety Laboratory Tests: hematocrit, hemoglobin, red blood cells, platelets, white blood cells, differential white blood cells count, sodium, potassium, calcium, serum creatinine, urea, serum albumin, total bilirubin, fractionated bilirubin, ALT, AST, ALP, lypases and amylases [time frame: end of treatment visit (Week 1) or early withdrawal]., Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [time frame: throughout the study].
Interventions
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change From Baseline in Average Daily Low Back Pain (LBP) Intensity as Measured by an 11-point Numeric Rating Scale (NRS) at the follow-up visit [Time Frame:, Day 21], Change from baseline in Neuropathic Pain Symptom Inventory (NPSI) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at week 1, Change from baseline in Douleur Neuropathique en 4 Questions (DN4) score at the follow-up visit [ Time Frame: Day 21], Number of Participants Withdrawn Due to Lack of Efficacy Week 1, Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 1, Change from Baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 1, Patient Global Impression of Change (PGI-C) Score Week 1, Change From Baseline in European Quality of Life Questionnaire-5 Dimension-5 Level (EQ-5D-5L) to Week 1, Change From Baseline in Work Productivity and Activity Impairment (WPAI) Instrument at Week 1, Number of rescue interventions up to | — |
Countries
Italy, Spain